New combo therapy vs capecitabine for biliary tract cancer after surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if a combination of immunotherapy (durvalumab), chemotherapy (GEMOX or GC), and a targeted therapy (lenvatinib) works better than standard capecitabine chemotherapy to prevent cancer from coming back after surgery for bile duct or gallbladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery to remove all visible bile duct or gallbladder cancer (R0 or R1 resection).
- You are between 18 and 75 years old.
- You are in good daily activity level (ECOG score 0 or 1).
- Your blood counts and liver/kidney function tests are within certain limits.
- You have not received prior immunotherapy or chemotherapy for this cancer.
- You are willing to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding another drug (lenvatinib or chemotherapy) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for advanced bile duct or gallbladder cancer that has not been treated before. It aims to find a more effective first treatment option.
This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy (GemOX) and lenvatinib can shrink tumors enough so that bile duct or gallbladder cancers that could not be removed initially become eligible for surgery. It is an option for people with advanced but not yet spread cancer who have not received prior treatment.
This study tests whether combining chemotherapy and radiation therapy after surgery improves outcomes for patients with bile duct or gallbladder cancer. It's designed for patients whose surgery showed signs the cancer might come back.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
This trial tests a combination of three drugs (irinotecan liposome, capecitabine, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has worsened after one prior treatment. It may be an option if you haven't taken capecitabine or lenvatinib before and are generally feeling well.
Hear when a new Biliary Tract Neoplasms Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.